Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Favored Vehicle for Seniors: Make Your Determination - 2Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- 3Meet the astronauts about to make history on flight around the moon
- 4Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
- 5AstraZeneca to invest $2 billion as part of US manufacturing push
- Instructions to Expand Your Advantages from an Open Record Reward
- Flu season is ramping up, and some experts are "pretty worried"
- 25 Most Beautiful Villages in France You Can Actually Visit
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- Vote in favor of your favored spot to peruse
- IDF strikes Hamas terror base in Lebanon, Health Ministry says 11 killed
- Marvel's X-Men are joining the battle in 'Avengers: Doomsday': Watch the teaser
- Skeleton of famed musketeer possibly found in Dutch church
- Video of clashes over purported conscription orders misrepresented as anti-war protest in Israel
